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Abstract
Background: Eicosapentaenoic acid (EPA) may reduce increased risks for (cardiovascular) morbidity and mortality in patients
with diabetes mellitus (DM) and comorbid major depressive depression (MDD). Yet, effects of EPA-supplementation on
biological risk factors for adverse outcomes have not been studied in DM-patients with MDD.
Methods:We performed a randomized, double-blind trial (n = 25) comparing add-on ethyl-EPA-supplementation to placebo
on (I) oxidative stress, (II) inflammatory, (III) hypothalamic-pituitary-adrenal (HPA)-axis, (IV) one-carbon-cycle, (V) fatty acid
metabolism and (VI) lipoprotein parameters during 12-weeks’ follow-up.
Results: Besides increases in supplemented a-tocopherol [estimate (95% CI); 3.62 (1.14–6.11) mmol/l; p = 0.006] and plasma
and erythrocyte EPA, the intervention did not influence other oxidative stress, inflammatory or one-carbon-cycle parameters
compared to placebo. HPA-axis reactivity significantly decreased in the EPA-group (N = 12) [AUCi:2121.93 (2240.20–23.47)
min6nmol/l; p = 0.045], not in the placebo-group (N= 12). Furthermore, EPA-supplementation increased erythrocyte and
plasma docosapentaenoic acid, and decreased plasma arachidonic acid (AA) concentrations [21.61 (23.10–20.11) %;
p = 0.036]. Finally, EPA had a multivariate influence on lipoprotein concentrations (p = 0.030), reflected by relative increases
in high density lipoprotein [HDL; 0.30 (0.02–0.58) mmol/l; p = 0.039] and total cholesterol concentrations [1.01 (0.29–1.72)
mmol/l; p = 0.008].
Conclusion: Overall, add-on EPA-supplementation had limited effects on biological risk factors for adverse outcome in this
sample of DM-patients with comorbid MDD. Besides increases in concentrations of supplemented a-tocopherol and EPA,
AA decreased, and inconclusive effects on HPA-axis (re)activity and lipoprotein concentrations were observed. Therefore,
further studies on the alleged beneficial effects of EPA-supplementation on biological risk factors for adverse outcome in
DM-patients with comorbid MDD seem warranted, preferably using clinical outcomes such as (cardiovascular) DM-
complications.
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Introduction
The prevalence of Major Depressive Disorder (MDD) in
patients with type 1 or type 2 diabetes mellitus (DM) is twice
that of persons without DM [1]. Importantly, in DM-patients, a
diagnosis of comorbid MDD is not only associated with impaired
quality of life [2], but also with an increase in (cardiovascular)
complications, functional disability, and all-cause mortality [1,3,4].
Although the association between MDD and adverse DM-
outcomes may be due to debilitating effects directly related to
DM itself (e.g. comorbidities), this association between MDD and
adverse DM-outcomes could also be mediated by underlying
common biological mechanisms [3,5,6].
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Both MDD and DM are independently associated with diverse
endocrinological and metabolic disturbances compared with
healthy controls. For example, it has been reported that MDD-
and DM-patients have (I) increased oxidative stress [1,7], together
with (II) immune activation [1,7–9], (III) hypothalamus-pituitary-
adrenal (HPA)-axis hyperactivity [5], and (IV) one-carbon-cycle
alterations [10,11]. In addition, in both disorders, disturbances in
lipid metabolism have been found with (V) lower concentrations of
long chain v3 polyunsaturated fatty acids (PUFA) [12–15] and
(VI) altered lipoprotein concentrations [16–18].
These endocrinological and metabolic disturbances could be
seen as a general resemblance of both biological and oxidative
stress and its associated allostatic load [7,19]. Indeed, these
biological disturbances have individually been shown to act as risk
factors for adverse outcomes in DM patients [11,18,20–23].
Therefore, it could be hypothesized that the biological distur-
bances associated with MDD add up to those in DM and thereby
act as pathogenetic mediators explaining the accelerated and
exaggerated development of adverse health outcomes in DM-
patients with a comorbid MDD-diagnosis [24].
Normalization of these MDD-associated endocrinological and
metabolic disturbances might therefore improve DM-outcomes.
However, in clinical practice, treatment for MDD in DM-patients
remains problematic, with low remission- and high relapse-rates
[23]. Moreover, antidepressants are not always successful in the
treatment of possible biological pathogenetic mediators of adverse
outcomes, e.g. glycemic control, and may even have adverse
effects [25,26]. These findings emphasize the need for more
effective treatment of comorbid MDD in DM-patients, in
particular for the MDD-associated biological disturbances. One
candidate may be PUFA from fatty fish, particularly eicosapen-
taenoic acid (EPA; C20:5v3) [23,27].
Add-on supplementation of EPA in DM-patients with MDD did
not prove to be effective on MDD-symptoms [28]. However,
besides merely clinical effects, EPA has been suggested to have
additional effects on the above mentioned biological disturbances
associated with DM and MDD. EPA is thought to lower oxidative
stress levels [29–31], possibly through its attenuating effects on
immune activation [32,33] and HPA-axis activity [34–36]. This
would fit with observations of beneficial influences of EPA on
oxidative stress associated allostatic alterations, such as a shift of
the one-carbon cycle in the remethylation direction [37] and
increases in high density lipoprotein (HDL) cholesterol [32,38].
Furthermore, EPA-supplementation alters FA-metabolism with
increases in v3- and decreases in v6-PUFA concentrations [39].
Therefore, despite the lack of effects on MDD-symptoms, EPA
might improve outcomes in DM-patients with comorbid MDD
through its influence on biological risk factors for adversities
associated with the comorbid MDD.
However, in contradiction to the above described lowering
effects of EPA on oxidative stress, EPA-supplementation has also
been suggested to increase oxidative stress. Because EPA is
polyunsaturated, it is highly susceptible to peroxidation [40]. Both
in and ex vivo, EPA may be subject to lipid peroxidation,
conceivably resulting in potentially harmful lipid peroxidation
products [40–42]. These lipid peroxidation products may coun-
teract the possible beneficial effects of EPA-supplementation and
thereby cause inconsistencies in the results of EPA-supplementa-
tion studies [40].
To our knowledge, the effects of EPA-supplementation on
biological risk factors for adverse outcomes have not yet been
studied in DM-patients with comorbid MDD. Therefore, we
carried out a randomized, double-blind, placebo-controlled trial in
which we performed planned secondary analyses to test the effects
of add-on EPA-supplementation on (I) oxidative stress parameters,
(II) immune activation, (III) HPA-axis activity, (IV) one-carbon-
cycle parameters, (V) FA-metabolism and (VI) lipoprotein
concentrations.
We hypothesized that EPA-supplementation would reduce (I)
oxidative stress, (II) immune activation, and (III) HPA-axis
reactivity. In addition, we hypothesized that EPA-supplementation
would (IV) shift the one-carbon-cycle in the remethylation
direction, (V) increase v3- and decrease v6-PUFA concentrations,
and (VI) increase HDL-cholesterol.
Methods
Study design and participants
The study-design has been described in detail previously [28]
(see supplementary material for trial protocol, translation and
CONSORT checklist). In brief, we recruited patients from the VU
University Medical Center diabetes outpatient clinic and through
advertisements on websites, in newspapers, and patient magazines,
with both MDD and DM to participate in a randomized, double-
blind, placebo-controlled, balanced parallel-group study on the
effects of EPA-supplementation on MDD-symptoms and biolog-
ical risk factors for adverse DM-outcome. We included partici-
pants aged 18–75 years, diagnosed with DM (type 1 or 2) and
MDD, and who used their current antidepressant medication for
at least two months. To determine whether patients fulfilled the
DSM-IV criteria for MDD we used the Composite International
Diagnostic Interview (CIDI) [43]. We regarded subjects as DM-
patients when they were diagnosed with DM in their medical
status, used oral hypoglycemic agents and/or insulin. Exclusion
criteria included pregnancy, serious comorbid disease, using fish
oil supplements, consuming more than three servings of fish per
week, alcohol or drug abuse, suicidal ideation, and allergy to fish,
fish products or rapeseed oil. We recruited participants from April
2006 until May 2007 and performed the trial between June 2006
and July 2007. The study protocol was approved by the ethical
committee of the Vrije Universiteit (VU) University Medical
Center. All participants gave written informed consent.
Intervention
Randomization occurred with computer-generated random
numbers, performed by an employee of the pharmacy of the
VU University Medical Center, who was not involved in the data
collection and analysis. Patients were randomly allocated to
1 gram/day fish oil, containing .90% ethyl-ester EPA, or an
equivalent dose of rapeseed oil and medium chain triglycerides
(placebo). The EPA and placebo were packed in 500 mg soft
gelatin capsules identical in appearance, and provided by Minami
Nutrition, Belgium. To protect against lipid peroxidation, we
stabilized the capsules with mixed tocopherols [40]. Peroxidiz-
ability differed between the EPA and placebo capsules, so different
concentrations of tocopherols (Vitamin E) were added. The EPA
capsules contained 11.3 g/L d-tocopherol, 27.7 g/L 3-tocopher-
ol, and 3.6 g/L a-tocopherol, and the placebo capsules contained
12.8 g/L d-tocopherol, 29.3 g/L 3-tocopherol, and 1.7 g/L a-
tocopherol. We instructed patients to consume two capsules per
day for 12 weeks in addition to their anti-depressant therapy. We
advised patients not to chew the capsules. Patients, the research
nurse and researchers were blinded for treatment allocation until
completion of the data-collection.
Measurements
General. The day before starting either the intervention or
placebo treatment, we conducted a baseline measurement (week 0)
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at the VU medical centre. Herein, we asked age, gender,
educational level, cohabiting status, level of fish consumption
during the last month, and use of fish oil supplementation. In
addition, we obtained information on smoking habits, weight,
height, DM-type, DM-treatment, and DM-complications. We
collected blood samples after an overnight fast both in serum tubes
and EDTA plasma tubes by venapuncture at baseline and in week
12. Both tubes were centrifuged within 2 hours after blood
withdrawal. Serum samples were divided into 0.5 mL aliquots and
stored at 280uC until analysis. The erythrocytes from the EDTA
plasma tubes were washed two times with saline and subsequently
stored at 280uC until analysis. Analyses were performed by the
National Institute for Public Health and the Environment (RIVM)
on the following factors. All measures were performed in serum,
unless otherwise stated. Intra-assay variability was well below 8%
for all measures (Table S1). The inter-assay variability was not
determined because all samples have been analyzed in the same
assay.
Oxidative stress. Since there is no single leading biomarker
of oxidative stress [44], we measured a set of six parameters to get
an indication of the levels of oxidative stress present in the patients.
First, we measured concentrations of reactive oxygen species
(ROS), as instigators of oxidative stress, using the dROMs kit from
Diacron, Grosseto, Italy. Higher ROS concentrations indicate
more oxidative stress. In addition, we measured concentrations of
malondialdehyde, an often used biomarker of oxidative damage to
lipids [7,44], by high performance liquid chromatography using a
kit from Chromsystems, Munich, Germany. For malondialdehyde,
higher concentrations also indicate more oxidative stress damage.
Furthermore, we included several markers of anti-oxidative
capacity. First, we analyzed the gluthathione system in erythro-
cytes, the most important anti-oxidative defense system [44], and
expressed it in the ratio of oxidized glutathione to reduced
glutathione (GSSG/GSH). A higher ratio reflects more oxidative
stress. Total glutathione (GSHtot) and oxidized gluthation (GSSG)
have been measured after deproteinization by using glutathione
reductase and DTNB. GSSG is determined after derivatization of
GSH by 2-vinylpyridine on an autoanalyser. In addition, we
measured vitamin E concentrations by reversed phase HPLC with
fluorescence detection, in the form of 3-tocopherol (the major
form in human diet) and a-tocopherol (the most extensively
studied form) [45]. Vitamin E is the major membrane antioxidant
necessary for the renewal of cells and to inhibit inflammatory
lesions [7,44,46]. Finally, we measured activity of superoxide
dismutases (SOD) in erythrocytes, using a kit from Randox
Antrim, GB. SOD detoxificate superoxide, and thereby contribute
to the antioxidant defense [7]. Higher SOD-activity is consistent
with high levels of oxidative stress.
Inflammation. As indication of inflammatory activity in our
patients, we assessed three inflammatory biomarkers. We mea-
sured concentrations of C-reactive protein (CRP) by a dedicated
high-sensitive kit from Beckman-Coulter, Woerden, the Nether-
lands. We determined interleukin-6 (IL-6) and tumor necrosis
factor-a (TNF-a) using high-sensitive enzyme immune-assay kit
from R&D Systems, Abingdom, GB. These clinically relevant
markers of inflammation are associated with complications in DM
[21] and related to MDD [9,47].
One-carbon-cycle. To assess one-carbon-cycle metabolism
[10], we measured concentrations of vitamin B12, folate and
homocystein, using a kit from Dialab, Vienna, Austria.
Fatty acids. In erythrocyte phospholipids, we measured EPA,
docosapentaenoic acid (DPA; 22:5v3) and docosahexaenoic acid
(DHA; 22:6v3) by gas chromatography (GC-3900, Varian Assoc.,
Palo Alto, USA). In addition, we measured concentrations of 33
FA in the phospholipid fraction in serum, including EPA, DHA,
arachidonic acid (AA; C20:4v6), and nervonic acid (NA;
C24:1v9). The FA-content was expressed as percentage of the
total fatty acids present in the chromatogram. Subsequently, we
calculated three indices to delineate important structural FA-
characteristics [48]. These indices were the unsaturation index
(UI), chain length index (CLI) and peroxidation index (PI),
according to previously defined formulas [49]. The UI provides
information about the mean number of double bounds per FA, the
CLI denotes the mean FA-chain length, while the PI indicates the
mean FA susceptibility to oxidative stress.
Lipoproteins. We measured cholesterol concentrations in
low and high density lipoproteins (LDL, HDL) together with total
cholesterol, using dedicated kits from Beckman-Coulter, Woerden,
the Netherlands. In addition, we calculated the total/HDL
cholesterol ratio.
HPA-axis. We measured HPA-axis activity by determining
salivary cortisol by enzyme immunoassay using a kit from DSLabs,
Beckman-Coulter, Germany. Subjects collected saliva using
salivettes at awakening, 30 minutes, 45 minutes and 1 hour
thereafter, also at baseline and week 12. After centrifuging, the
clear saliva samples were stored at 220uC until analysis. For
practical reasons, the cortisol concentrations at awakening, 30 and
45 minutes, and 1 hour thereafter for both baseline and follow-up
measurements were reformulated in area-under-the-curveground
(AUCg; total hormonal output) and area-under-the-curveincrease
(AUCi; changes over time) scores in accordance to previously
described formulas [50].
Statistical analyses
We calculated sample size for the study using G*Power 3.0.10,
for the within-between interaction for the original study’s primary
outcome variable – MDD-symptom severity – as described
previously [28]. As seven repeated measures of MDD-symptom
severity were obtained, 10 patients had to be randomized to each
intervention group to detect a standardized effect size of f = 0.25
for the primary outcome variable (power 80%, two-sided a= 0.05,
correlation between repeated measures = 0.6 and non-sphericity
correction e= 0.6). We assumed a drop-out of 20%, so 25 patients
were included. In the present investigation our biological outcome
variables were measured twice. Hence, the reported sample size
calculation does not apply to the present investigation. Therefore,
we recalculated the power for the biological outcome variables in
analogy to the power calculations for the primary outcome
variable, by changing the number of measurements in G*Power
from 7 to 2. With 80% power and the assumed 20% drop-out, this
resulted in a detectable effect size of 0.30 instead of 0.25 for the
biological outcome variables under investigation in the present
study.
Intention to treat analyses were conducted. Outcome variables
that were not normally distributed were log-transformed to
achieve normality. Because our pathophysiological characteristics
(i.e. oxidative stress, inflammation, one-carbon-cycle, fatty acids
and lipoproteins, HPA-axis) consisted of multiple biomarkers, we
used repeated measures multivariate analyses of variance (MAN-
OVA) to test the effects of EPA-supplementation on these
outcomes. If the multivariate treatment6time interaction test
statistic was significant, we performed follow-up linear mixed
models for the individual variables. In case a genuine effect exists,
these subsequent mixed model analyses for the individual variables
are thought to be protected by the initial MANOVA [51,52].
From the mixed model analyses, we derived effect estimates for the
treatment6time interaction effects, together with 95% confidence
intervals in order to distinguish between absence of effect and
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absence of evidence of effect. The large number of biomarkers
tested makes it difficult to exclude type I errors, therefore, results
should be interpreted with caution. However, because our study is
of an explorative nature, we did not additionally correct for
multiple testing [52]. Furthermore, we reported indices of effect
sizes (i.e. partial g2 values and Cohen’s d) where appropriate.
Partial g2 values represent the proportion of the variance in the
dependent variable that can be explained by the independent
variables and were derived from repeated measures MANOVA;
0.01 indicates a small, 0.06 a moderate, while 0.14 indicates a
large effect. However, partial g2 has a tendency to overestimate
effect size, and thus should be interpreted with caution. Cohen’s d
was used to describe to magnitude of differences derived from
paired samples t-tests, when comparing the before and after
treatment states. For Cohen’s d, 0.2 indicates a small, 0.5 medium
and 0.8 a large effect. All analyses were performed in PASW
statistics 18.0 (SPSS, Inc., 2009, Chicago, IL).
Results
The participant flow, compliance and adverse events in this trial
have been described previously [28]. In brief, 75 persons initially
volunteered to participate in the study. Twenty persons were not
interested or had no time, 15 did not respond, and 12 were
excluded because they did not meet inclusion criteria (see Figure 1
for CONSORT flowchart). For three persons, reasons of non-
participation were unknown. Twenty-five patients were random-
ized to either EPA (n = 13) or placebo (n = 12), consisting of 13
women and 12 men with a mean age of 54 (611) years. At
baseline, the two intervention groups did not differ significantly
with regard to age, gender, smoking status, body mass index, fish
consumption, DM-type, DM-complications, DM-treatment,
HbA1c, MDD-severity, and oxidative stress, inflammatory,
HPA-axis, one-carbon cycle, and lipoprotein parameters, indicat-
ing successful randomization (Table S2). For the 33 baseline FA-
concentrations and 3 indices, the two intervention groups also did
not differ, except for erythrocyte membrane DPA (table 1,
p = 0.026) and plasma phospholipid 16:3v4 (EPA-group
0.1260.02; placebo-group 0.1560.04; p = 0.034). One EPA-
patient showed an allergic reaction and discontinued using EPA,
but no other severe adverse events were reported. Both baseline
and 12 weeks follow-up saliva and blood samples were available
for 19 and 24 patients, respectively. Baseline and follow-up means
of the concentrations of the biological parameters for the
intervention and placebo group are given in table 1.
Oxidative stress
The multivariate effect of the treatment6time interaction on the
six selected oxidative stress parameters was significant (F = 2.898;
p = 0.039; partial g2 = 0.506), indicating an effect of the supple-
mentation on the overall course of the parameters. Subsequent
linear mixed model analyses indicated that this multivariate result
was due to an increase in a-tocopherol in the EPA-supplemen-
tation group relative to the placebo group (table 2). The courses of
the other 5 measures of oxidative stress were not significantly
altered by EPA-supplementation in linear mixed model analyses
(table 2).
Inflammation
There was no significant multivariate effect of the treatment6
time interaction on the 3 inflammatory markers (F = 0.156;
p = 0.924; partial g2 = 0.025). Therefore, linear mixed models
were not indicated. This shows that EPA-supplementation had no
effect on inflammatory markers in our sample of DM-patients with
MDD, compared to placebo (for reasons of completeness,
univariate mixed model results of non-significant multivariate
biomarkers are shown in Table S3).
HPA-axis
The multivariate treatment6time interaction for the AUCg and
AUCi was not significant (F = 1.310; p = 0.297; partial g
2 = 0.141;
Figure 2). However, the high correlation between the two outcome
variables (Pearson’s r = .607; p = 0.006), and large variance
naturally present in cortisol concentrations may have increased
the chance of type II errors in MANOVA. Therefore, we
performed secondary analyses, in which we additionally tested
the difference between follow-up and baseline concentrations in
each intervention arm using paired samples t-tests. The follow-up
AUCg was not significantly different from the baseline measures,
in both the EPA-supplementation-group (t =21.505; df = 8;
p = 0.171; Cohen’s d =20.709) and the placebo-group (t = 0.486;
df = 9; p = 0.639 Cohen’s d = 0.217). However, the AUCi showed a
significant decrease in the EPA-group over time (t =22.374;
df = 8; p = 0.045; Cohen’s d =21.119), compared with a non-
significant change in the placebo-group (t =20.247; df = 9;
p = 0.810; Cohen’s d =20.110).
One-carbon-cycle
The multivariate test for the effect of the treatment6time
interaction was non-significant for the three one-carbon-cycle
factors: vitamin B12, folate and homocysteine (F = 1.212;
p = 0.331; partial g2 = 0.154). Therefore, linear mixed models
were not indicated.
Fatty acids
The multivariate treatment6time interaction-effect on the three
indices (UI, CLI and PI) reflecting main characteristics of FA-
metabolism was not significant (F = 1.355; p = 0.288; partial
g2 = 0.184). However, the multivariate treatment6time interac-
tion-effect for the FAs in the phospholipid fraction [oleic acid (OA;
C18:1v9), a-linolenic acid (ALA; C18:2v3), linoleic acid (LA;
C18:2v6), arachidonic acid (AA; C20:4v6), EPA, DPA, DHA,
and nervonic acid (NA; C24:1v9)] was significant (F = 5.151;
p = 0.005; partial g2 = 0.760). Subsequent linear mixed models
showed that this effect consisted of a significant treatment6time
interaction for AA, EPA, and DPA (table 2). This indicates that
EPA-supplementation particularly increased both EPA- and DPA-
concentrations, while it also decreased AA-concentrations com-
pared with the placebo-group. In the erythrocyte, a similar pattern
was observed with a significant multivariate treatment6time
interaction for EPA, DPA and DHA (F = 35.249;
p = 3.54561028; partial g2 = 0.841). Subsequent linear mixed
models also showed increases in EPA and DPA (table 2).
Interestingly, DHA-concentrations did not significantly change
over time in the EPA-group compared with the placebo-group in
both plasma and erythrocyte phospholipids (table 2).
Lipoproteins
The multivariate treatment6time interaction-effect on total
cholesterol, LDL and HDL was significant (F = 3.648; p = 0.030;
partial g2 = 0.354), indicating a significant effect of EPA on
changes in lipoprotein concentrations over time compared with
placebo. Subsequent linear mixed models revealed that this effect
consisted of a relative increase in HDL and total cholesterol
concentration in the EPA-group (table 2). Differences in LDL-
concentrations over time did not significantly differ between the
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two groups (table 2). The multivariate treatment6time interaction-
effect was not significant for the total/HDL cholesterol ratio.
Discussion
In this randomized, double-blind, placebo-controlled trial, we
found limited effects of add-on EPA-supplementation on measured
biological risk factors in a sample of DM-patients with comorbid
MDD. First, supplementation relatively increased a-tocopherol
concentrations, but EPA had no effects on other parameters of
oxidative stress compared to placebo. Second, changes in
inflammatory markers were not significantly different between
the two groups. Third, reactivity of the HPA-axis diminished in
the EPA-group, while, fourth, EPA had no significant influence on
one-carbon-cycle parameters. Fifth, though FA-indices were not
significantly altered by EPA-supplementation, individual FA-
concentrations were influenced with increases in EPA- and
DPA-concentrations and decreases in AA. Finally, sixth, EPA
increased HDL and total cholesterol relative to placebo. To the
best of our knowledge, this is the first study investigating the
biological effects of EPA in DM-patients with comorbid MDD.
Oxidative stress
Our results suggest that supplementation significantly increased
a-tocopherol, consistent with previously reported increases in a-
tocopherol after supplementation in MDD [53]. This increase
likely reflects the higher a-tocopherol content in the EPA-capsules
compared to placebo, necessary to prevent EPA from lipid
peroxidation [40]. EPA had no effects on ROS, malondialdehyde,
the GSSG/GSH ratio and SOD activity, neither consistent with
increasing nor decreasing effects of EPA-supplementation on
oxidative stress in this sample. Data regarding the effects of EPA
on oxidative stress in other populations available thus far remain
inconclusive [54], with some studies reporting lowering effects
[29], and others absence of [37], or even increasing effects [40,41].
Nevertheless, particularly our finding of no increasing effects of
Figure 1. Flow diagram.
doi:10.1371/journal.pone.0049431.g001
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EPA supplementation on malondialdehyde, indicates that the
supplemental EPA is not subject to lipid peroxidation. The
possibility that harmful lipid peroxidation products are formed is
thereby reduced, so our results form no contraindication for future
supplementation studies in depressed DM-patients that can further
clarify these issues.
Inflammation
Although EPA is thought to suppress inflammatory responses
[55], we did not find any differences in changes of CRP, IL-6, and
TNF-a compared to placebo. For CRP, a suppressive effect of
EPA was found in DM-subjects [32], but not consistently [29]. We
are not aware of any studies on the effects of EPA on CRP in
MDD. For IL-6, our findings are in agreement with studies on
subjects with either DM [29,32] or MDD [36]. With regard to
TNF-a, our findings of a lack of effect of EPA are similar to some
[29], but not all previous research in DM [32], while MDD-
patients have not been studied. These inconsistent findings could
be because some studies are not placebo-controlled [32], which
may have affected results. The absence of effects of EPA on
inflammatory markers in our and previous placebo-controlled
trials could be explained by anti-depressant and/or diabetic
Table 1. Means and standard deviations of several biological parameters in patients with diabetes mellitus and co-morbid
depression (n = 24) before (baseline) and after (follow-up) 12-week randomized add-on supplementation of either ethyl-
eicosapentaenoic acid or placebo.
Parameter Baseline EPA Follow-up EPA Baseline placebo Follow-up placebo
ROS, U/ml 440.25684.33 424.33690.45 395.67651.49 392.25658.62
MDA, mmol/l 0.5260.21 0.4960.19 0.4760.15 0.4260.18
GSSG/GSH ratio 0.3460.12 0.3160.10 0.3560.13 0.2660.07b
3-tocopherol, mmol/l 3.6861.55 5.2661.63 4.5261.27 6.5163.60b
a-tocopherol, mmol/l 26.1163.51 27.2463.33c 28.9163.65 26.4263.37b
SOD, U/mmol Hb 11.5166.94 12.4666.34 13.1064.16 10.7061.14
CRP, mg/la 3.26 (6.08) 3.92 (6.90) 3.79 (4.90) 3.47 (6.50)
IL-6, pg/mla 2.20 (2.91) 2.18 (1.09) 2.20 (1.84) 2.24 (1.60)
TNF-a, pg/mla 2.11 (0.66) 1.97 (0.92) 2.32 (1.56) 2.09 (1.38)
AUCg 537.586227.54 424.426115.39 488.186255.70 526.436315.18
AUCi 145.586167.45 23.756166.20
d 148.586229.44 136.426248.35
Vitamine B12, pg/ml
a 268.50 (141.25) 299.50 (99.75) 276.00 (118.00) 296.00 (173.50)
Folate, nmol/la 13.20 (7.71) 12.53 (9.07) 13.29 (8.84) 16.66 (12.56)
Homocystein, mmol/l 13.3164.80 13.7564.95 16.1665.34 16.1765.12
Erythrocyte EPA, % 0.5460.17 1.6960.56c,e 0.6660.20 0.6160.19
Erythrocyte DPA, % 2.1760.39f 3.5060.71c,e 2.5760.46 2.5560.44
Erythrocyte DHA, % 4.4760.83 4.3560.93 4.7561.19 4.7961.01
Peroxidation index 1.1260.14 1.1660.13 1.1160.06 1.1260.11
Chain length index 18.0760.09 18.0860.10 18.0660.07 18.0760.07
Unsaturation index 1.3960.09 1.4060.07 1.3760.04 1.3860.07
Linoleic acid, % 21.2664.10 20.8963.15 21.0461.97 20.9962.78
Arachidonic acid, % 10.8262.23 9.9162.02g 9.8661.78 10.4562.47
a-linolenic acid, % 0.1460.07 0.1860.08 0.1960.09 0.1860.08
EPA, % 0.8860.42 2.2461.06d,e 0.9660.23 0.8760.34
DPA, % 0.9060.27 1.3460.46c,g 1.0560.25 1.0260.28
DHA, % 3.0761.03 2.8560.85 3.1760.96 3.2160.87
Oleic acid, % 8.1960.77 8.0560.60 8.8562.02 8.7861.71
Nervonic acid, % 1.1760.42 1.2260.30 1.2460.23 1.3860.36
LDL cholesterol, mmol/l 2.6560.85 2.6961.07 3.2061.10 2.6960.74
HDL cholesterol, mmol/l 1.1760.30 1.2760.64 1.4260.53 1.2360.38b
Total cholesterol, mmol/l 4.6060.84 4.7661.17 5.3861.20 4.5360.89b
Total/HDL cholesterol ratio 4.1661.29 4.2061.65 4.1061.16 3.8360.78
aMedian (Inter-quartile range), significance non-parametrically tested.
bSignificantly different from baseline concentrations in the placebo-group (P,.05).
cSignificantly different from baseline concentrations in the EPA-group (P,.001).
dSignificantly different from baseline concentrations in the EPA-group (P,.05).
eSignificantly different from follow-up concentration in the placebo-group (P,.001).
fSignificantly different from baseline concentrations in the placebo-group (P,.05).
gSignificantly different from follow-up concentration in the placebo-group (P,.05).
doi:10.1371/journal.pone.0049431.t001
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medication patients received, which could have normalized
inflammatory marker concentrations [56]. This is supported by
relatively modest baseline concentrations of inflammatory markers
in our sample. In that case, the possibility for EPA to normalize
concentrations would be reduced.
HPA-axis
Analyses of variance showed no differences in the courses of the
HPA-axis measures between placebo and control groups. This
could indicate that EPA had no effect on the HPA-axis in this
sample. However, as noted previously, this absence of effects might
also be due to type II errors [57], because of strong correlations
between outcome variables and large natural variability in cortisol
concentrations. Our findings that in the EPA group, AUCi
significantly decreased (with a large effect size), compared to no
significant changes in the placebo group (Figure 2), might also hint
in this direction [57]. A decreasing effect of EPA on the AUCi
would be in accordance with previously reported effects of EPA-
supplementation on cortisol in MDD [36]. DM-patients have not
been studied, but in healthy subjects, fish oil (rich in EPA)
supplementation caused blunted cortisol concentrations after
mental stress [34] or an endotoxin challenge [58], in accordance
with our results and those in rats [59]. However, overall, effects of
EPA-supplementation on cortisol in this sample of DM-patients
with comorbid MDD remain inconclusive.
One-carbon-cycle
In our sample of DM-patients with MDD there was no evidence
for an effect of EPA-supplementation on one-carbon-cycle
parameters. Data on MDD-patients are not available. In DM-
patients, previous findings of homocysteine decreasing effects of
v3 PUFA supplementation contradict our findings [37,60], as do
findings in healthy women [31]. Apart from differences in study
population, this could be due to the use of other supplementation-
products (ethyl-EPA vs. v3 PUFA in general). In addition,
increases in homocysteine concentrations after fish oil supplemen-
tation were observed in healthy subjects, without effects on folate
or vitamin B12; these latter two findings in accordance with our
study [61].
FA-concentrations
While EPA did not affect overall structural FA-indices (UI, CLI,
PI), it increased EPA-concentrations, as expected and reported in
previous papers [28,62], and also DPA-concentrations. This
corresponds with previous findings in DM or MDD
[39,53,63,64], and also suggests good study compliance. Supple-
mentation also decreased AA-concentrations compared with the
placebo-group, this is in agreement with some [39], but not all
previous findings in DM [63], while in MDD it was shown that
supplementation decreased total v6 FAs [53]. The inconsistencies
between our findings and those of Rondanelli et al. considering the
effect of EPA on AA [63], may be due to differences in study
population (elderly subjects with MDD or dysthymia vs. subjects
with MDD and DM), or intervention characteristics (1.67 gram
EPA and 0.83 gram DHA vs. 1 gram.90% ethyl-ester EPA). Our
observation of a lack of effect of EPA on DHA corresponds to a
previous report in DM [64], but not in MDD [53]. This lack of
effect, contrary to our hypothesis, could possibly imply that DHA-
concentrations are, possibly adaptatively, endogenously regulated
in these patients [14], and therefore less affected by increased
dietary availability of the DHA precursor EPA [65]. Considering
the association between DHA and brain derived neurotrophic
factor (BDNF) [66], this is consistent with the absence of effects of
EPA on BDNF in our sample [62]. The observed increases in DPA
could resemble the difference in baseline concentrations between
the EPA and placebo group. However, because we compared
baseline values of 33 FA and 3 indices, and groups were based on
randomization, this could be due to chance. In addition, both
erythrocyte and plasma DPA concentrations showed a marked
increase in the EPA-group. Therefore, these increases in DPA-
concentrations are likely caused by the EPA-supplementation, and
could possibly function as a storage form for later conversion to
DHA [67].
Lipoproteins
EPA increased HDL and total cholesterol, without significant
differences in LDL. These findings are not consistent with a meta-
analysis in DM-patients, which reported non-significant HDL
increases, absence of changes in total cholesterol and increases in
LDL [68]. However, a randomized controlled trial in MDD
patients also showed HDL increases after fish oil supplementation
[53]. So, it could be hypothesized that EPA has a different effect
on lipoprotein concentrations in MDD than in DM. The increase
in HDL concentrations in the EPA-group relative to placebo
coincides with increases in total cholesterol concentration, also
reflected by absence of a treatment effect on the total/HDL
cholesterol ratio. So, our data do not allow definitive conclusions;
Table 2. Linear mixed model treatment6time interaction
effects for selected biological parameters from significant
repeated measures MANOVA’s in diabetes patients with MDD
during 12-week randomized add-on supplementation of
either ethyl-eicosapentaenoic acid or placebo (n = 24).
Parameter EstimateSE 95% CI t P
ROS, U/ml 212.50 17.55 248.91–23.91 20.71 .484
MDA, mmol/l 0.018 0.089 20.166–0.201 0.20 .845
GSSG/GSH ratio 0.077 0.048 20.022–0.18 1.61 .121
3-tocopherol, mmol/l 20.41 0.90 22.28–1.47 20.45 .658
a-tocopherol, mmol/l 3.62 1.20 1.14–6.11 3.02 .006
SOD, U/mmol Hb 3.19 3.05 23.11–9.49 1.05 .306
Erythrocyte EPA, % 1.19 0.13 0.91–1.47 8.85 1.0161028
Erythrocyte DPA, % 1.34 0.13 1.08–1.61 10.5 4.26610210
Erythrocyte DHA, % 20.16 0.15 20.47–0.15 21.05 .304
Linoleic acid, % 20.28 0.83 22.00–1.44 20.34 .737
Arachidonic acid, % 21.61 0.72 23.10–20.11 22.24 .036
a-linolenic acid, % 0.05 0.03 20.02–0.12 1.61 .126
EPA, % 1.54 0.31 0.89–2.19 4.92 7.0061025
DPA, % 0.46 0.08 0.29–0.63 5.53 1.3961025
DHA, % 20.25 0.33 20.94–0.43 20.78 .445
Oleic acid, % 20.04 0.48 21.05–0.96 20.09 .933
Nervonic acid, % 20.09 0.11 20.32–0.14 20.79 .440
LDL cholesterol,
mmol/l
0.56 0.34 20.15–1.27 1.63 .117
HDL cholesterol,
mmol/l
0.30 0.14 0.02–0.58 2.19 .039
Total cholesterol,
mmol/l
1.01 0.34 0.29–1.72 2.92 .008
Total/HDL cholesterol
ratio
0.31 0.27 20.24–0.87 1.18 .251
doi:10.1371/journal.pone.0049431.t002
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further research on the effects of EPA-supplementation on
concentrations of oxidized forms of lipoproteins may yield
additional relevant results.
Limitations and strengths
Our study has several limitations. First, power was initially
calculated to detect effects of EPA on MDD-symptom severity for
which 7 repeated measurements were available [28], instead of the
2 repeated measurements (baseline and follow-up) for the
biological outcomes in the present study. In the initial power
calculations, the power was 80% to detect an effect size of 0.25
[28]. Considering the 2 repeated measures for the biological
outcomes in the present study, calculated power was 80% for an
effect size of 0.30. The decreased power due to less repeated
measures could have resulted in non-detection of true effects with
a small effect size. Nevertheless, the remaining power was
adequate to detect effects with a medium to large effect size. In
addition, the relatively small number of drop-outs (less than the
expected 20%) resulted in enough power to detect effects with
effect sizes between 0.25 and 0.30 for most outcome variables.
Second, the DM-group included both type 1 and type 2 DM-
patients. It may be that the effects of EPA on the measured
biological factors in our patients with DM and MDD are
modulated by DM-subtype. Our results are therefore only
generalizable to the whole population of patients with DM and
MDD, not specifically to only those patients with DM type 1 or
type 2.
Third, the absence of effects of EPA on markers of inflamma-
tion and the one-carbon-cycle may be because the dose was not
sufficient [69], the follow-up time was not long enough, or EPA
exerts its effects on still other markers than those we selected [55].
Fourth, the intervention capsules in our study contained no
DHA. Although EPA is thought to be more effective for treatment
of depressive symptoms [23,27], it could be that the effects of fish
oil on measured biomarkers are mainly caused by DHA. Future
studies using different concentrations of EPA in combination with
DHA could further clarify this issue.
Our study also has its strengths. To our knowledge, this is the
first study on the biological effects of EPA-supplementation in
DM-patients with comorbid MDD. This is clinically relevant
because these diseases have a large contribution to the global
burden of disease [4]. In addition, there was only a small loss to
follow-up. Also, because EPA was not effective in diminishing
MDD-symptoms in this population [28], effects of EPA have to be
directly related to its metabolic actions, not modulated by effects
on the comorbid MDD. Furthermore, we were able to investigate
several aspects of the biological influence of EPA at the same time.
Finally, the add-on randomized, double-blind, placebo-controlled
trial-design provided the opportunity to assess the preventive
causal effects of EPA on clinically relevant risk factors for adverse
outcome in a naturalistic setting.
General considerations
Besides increases in the supplemented products (a-tocopherol
and EPA), the intervention increased DPA, and decreased AA
concentrations compared to placebo. Additionally, EPA had
inconclusive effects on HPA-axis (re)activity and lipoprotein
concentrations. There were no changes in oxidative stress and
inflammatory markers or one-carbon metabolism. In addition,
significance levels of effects would not have survived strict
correction for multiple testing. Overall, this points to a limited
influence of EPA on risk factors for adverse outcome in this sample
of patients with DM and comorbid MDD.
Increases in the supplemented products (a-tocopherol and EPA)
and decreases in AA are generally considered beneficial [23,70],
but it remains to be determined whether exogenously induced
changes have similar effects. It could be hypothesized that the
observed decreases in AA and increases in EPA steered the
eicosanoid precursor supply in an anti-inflammatory direction
[24,55]. This would diminish oxidative stress, and the associated
Figure 2. Effects of EPA on cortisol. Cortisol concentrations at baseline and 12-week follow-up, in diabetic patients with comorbid depression
(n = 19) randomized to add-on supplementation of either ethyl-eicosapentaenoic acid or placebo. Error bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0049431.g002
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allostatic response. Alternatively, it could be hypothesized that the
improvement in allostatic load associated disturbances is mediated
through beneficial effects of EPA on transcription factors, e.g.
peroxisome proliferator-activated receptor (PPAR) and sterol-
responsive-element binding protein (SREBP) [71]. Through these
effects EPA could improve metabolic pathways, and for example
reduce insulin resistance and its associated oxidative stress [72].
However, since we found no effects of EPA on inflammatory,
other oxidative stress, or one-carbon metabolism biomarkers, it
seems that changes in concentrations of supplemented products
did not result in alterations in these allostase-associated potential
pathophysiological pathways [19]. On the other hand, EPA itself is
susceptible to oxidative stress, and harmful (non-)enzymatic lipid
peroxidation products may be formed, counteracting the possible
beneficial effects [40–42,73,74]. Our finding of no increases in the
lipid peroxidation product MDA, however, limits this risk.
EPA supplementation had no effect on mood in this sample
[28], and had limited effects on biomarkers for adverse outcome. It
may be possible that modulation of these risk factors would
actually be effective on both mood and adverse DM outcome, but
EPA supplementation may not be the optimal treatment to affect
these biomarkers. This possibility would still be in accordance with
hypothetical models of common pathophysiological pathways
underlying the relationship between DM and MDD (e.g.
inflammation, HPA-axis hyperactivity) [1,3,23], but would suggest
only a limited role for (exogenous) EPA. Besides existing effective
DM and MDD therapy (as also applied in the present study),
modulation of biomarkers from these pathways by other forms of
add-on treatment, such as physical exercise or cognitive therapy,
would then still be valuable topics for future research.
Conclusions
In this randomized placebo-controlled trial assessing the effect
of EPA supplementation in patients with DM and comorbid MDD
on a wide range of biomarkers for adverse outcome, we found
limited effects. Besides increases in the supplemented EPA and a-
tocopherol, AA decreased and DPA increased. Effects on the
HPA-axis and lipoprotein concentrations remain inconclusive.
There was no evidence for effects on biomarkers of oxidative
stress, inflammation, or one-carbon metabolism. Therefore, our
results emphasize the need for further investigation of the alleged
beneficial effects of add-on EPA supplementation in patients with
DM and MDD, preferably with clinical outcome measures such as
cardiovascular complication incidence, combined with adequate
assessment of the lipid peroxidation process.
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